House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith
  
Two zebras.
A long sought change to the Medicare drug price negotiation program benefiting orphan drug developers appears more likely to move through Congress this year. (Shutterstock)

More from Rare Diseases

More from Pricing Debate